Cancer drug trial aims to stop devastating weight loss
NCT ID NCT07146893
Summary
This early study is testing if a drug called selpercatinib can help cancer patients who are experiencing severe, unintentional weight loss and loss of appetite, a condition known as cachexia. It will involve a small group of patients with lung, colon, or pancreatic cancer who are already on chemotherapy. The main goal is to see if the drug is safe and feasible to use for this purpose and if it helps patients gain or maintain weight and strength over 12 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CACHEXIA-ANOREXIA SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73117, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.